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Six Out of Ten Women with 
Recurrent Urinary Tract Infections 
Complain of Distressful Sexual 
Dysfunction – A Case-Control Study
Luca Boeri1,2, Paolo Capogrosso1,3, Eugenio Ventimiglia1,3, Roberta Scano1, 
Alessandra Graziottin4, Federico Dehò1, Emanuele Montanari2, Francesco Montorsi1,3 & 
Andrea Salonia1,3
Uncomplicated recurrent urinary tract infections (rUTIs) are common among reproductive-aged women. 
We aimed to assess the prevalence and predictors of sexual dysfunction (FSD) in a cohort of women with 
rUTIs and compare their psychometric scores to those of matched controls. Data from 147 rUTIs women 
and 150 healthy controls were analysed. Participants completed the International Prostatic Symptoms 
Score (IPSS), the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (SDS). 
Descriptive statistics and logistic regression models tested prevalence and predictors of distressful 
FSD. Women with rUTIs had lower FSFI scores (p < 0.001) and a greater proportion of pathological 
FSFI (78.9% vs. 21.4%; p < 0.001) and SDS scores (77.8% vs. 21.4%; p < 0.001) than controls. Of rUTIs 
patients, 88 (60%), 77 (52.2%), and 75 (51.1%) reported pathological scores for FSFI-pain, lubrication 
and arousal, respectively; moreover, 64% had concomitant pathological FSFI and SDS scores. Age, IPSS 
severity, rUTIs, a history of ≥6 UTIs/year and a history of constipation were independent predictors of 
pathologic FSFI and SDS (all p ≤ 0.05). In conclusion, up to 80% of women with rUTIs showed pathologic 
FSFI and SDS scores, with 60% reporting scores suggestive of distressful FSD. Having ≥6 UTIs/year and 
a history of constipation independently predicted distressful FSD.
Uncomplicated urinary tract infections (UTIs) are among the most common bacterial infections encountered by 
women. Approximately 50% to 60% of women develop a UTI over their lifetime1, with one-third experiencing at 
least one by age 262. A recurrent UTI (rUTI) is widely defined as more than two episodes of uncomplicated UTI 
within 6 months or more than three within 12 months, as documented by urine culture3,4. It has been reported 
that nearly 20–30% of women with an episode of UTI will have a further episode, and around 25% of these will 
develop rUTIs2. Uropathogenic Escherichia coli (UPEC) is the pathogen responsible 70–95% of both sporadic 
and rUTIs5.
Despite being considered a mild and self-limiting condition, rUTIs have a detrimental impact on a patient’s 
quality of life (QoL)6,7, producing disabling effects on women’s health, intimate and social relationships, 
self-esteem, and capacity for work6, as well as irritability, tiredness and an inability to concentrate7. Increasing evi-
dence shows that sexual and urinary problems are often comorbid and possibly synergic with UTIs in women8–10. 
Moreover, 60% of rUTIs in women are postcoital5. Despite being clinically meaningful that urinary symptoms 
may be associated with sexual dysfunction and sexual bother, to the best of our knowledge no clinical study has 
examined the impact of rUTIs on women’s sexual functioning using validated psychometric questionnaires.
Given the significant prevalence of female sexual dysfunction (FSD) in the context of urologic disorders8–10 
and clinical observations of sexual complaints from women with rUTIs, we cross-sectionally sought to determine 
the prevalence and predictors of FSD in a cohort of white–European, heterosexual, sexually active women seeking 
medical help for rUTI as their primary complaint, and we compared their psychometric scores with those from a 
group of race- and age-matched women without rUTIs.
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Results
Table 1 lists the characteristics and descriptive statistics of the entire cohort of individuals. Overall, patients with 
rUTIs had experienced a mean (median) of 5.29 (6) UTI episodes throughout the previous 12 months. Out of 
147 women with rUTIs, 79 (53.7%) reported postcoital rUTIs. Almost 86.5% suffered from UPEC-related rUTIs, 
with other uropathogens (Enterococcus faecalis, Ureaplasma urealyticum, Klebsiella, Proteus Mirabilis) equally 
distributed (data not shown). Patients with rUTIs did not differ from controls in terms of age, BMI and CCI 
scores. Conversely, women with rUTIs more frequently showed a history of constipation (p = 0.006), were more 
frequently current smokers (p = 0.02) and were less likely to be in a stable sexual relationship (p = 0.04).
Table 2 depicts the descriptive statistics of the psychometric scores assessing sexual functioning and sexual 
distress among the cohort. Women with rUTIs showed significantly lower mean FSFI scores (p < 0.001) and 
had pathological FSFI scores more often than controls (78.9% vs. 21.4%; p < 0.001). When stratified, all FSFI 
sub-domains were significantly lower in the rUTIs than in –rUTIs individuals, with the exception of sexual desire. 
In the rUTIs group, 88 (60%), 77 (52.2%) and 75 (51.1%) women reported pathological FSFI-pain, lubrication 
and arousal subdomains, respectively. Similarly, patients with rUTIs had higher mean SDS scores (p < 0.001), 
and more pathological SDS scores (77.8% vs. 21.4%; p < 0.001) than controls. Overall, 64% of rUTIs women had 
concomitant pathological FSFI and SDS scores.
Considering only the rUTIs group, mean FSFI scores decreased with age (p = 0.03) and with increasing IPSS 
severity (p = 0.002) (Table 3). Moreover, the FSFI score was significantly lower in women with a history of consti-
pation (p < 0.001). Women with ≥ 6 episodes of UTI over the last 12 months reported worse FSFI, SDS and IPSS 
scores (all p ≤ 0.04), respectively, compared to women with < 6 UTIs per year. FSFI, SDS and IPSS scores did not 
vary according to BMI or CCI categories (Table 3).
−rUTIs +rUTIs p value (F)*
No. of patients 150 (50.5%) 147 (49.5%)
Age (years)
 Mean (SD) 34.5 (6.0) 35.3 (9.2) 0.71 (0.13)
 Range 24–48 19–50
BMI [kg/m2] 0.32 (0.99)
 Mean (SD) 21.3 (2.3) 22.0 (3.7)
 Range 17.6–29.4 15.6–35.4
BMI (NIH classification) [No. (%)] 0.39 (X2 = 1.85)
 18.5–24.9 139 (92.9) 124 (84.4)
 25–29.9 11 (7.1) 16 (10.9)
 ≥ 30 0 (0.0) 7 (4.8)
CCI 0.83 (0.43)
 Mean (SD) 0.29 (0.6) 0.26 (0.6)
 Range 0–2 0–3
CCI categorized [No. (%)] 0.45 (X2 = 0.56)
 0 118 (78.6) 124 (84.4)
 ≥ 1 32 (21.4) 23 (15.6)
Relationship status [No. (%)] 0.04 (X2 = 4.01)
 Stable sexual relationship 61 (41.5) 32 (21.4)
 No stable sexual relationship 86 (58.5) 118 (78.6)
Educational Status [No. (%)] 0.25 (X2 = 2.77)
 Primary/Secondary school 16 (10.7) 35 (23.8)
 High school 91 (60.7) 69 (46.9)
 University+ 43 (28.6) 43 (29.3)
Bowel History [No. (%)] 0.006 (X2 = 7.51)
 Normal 91 (60.7) 49 (33.3)
 Constipation 59 (39.3) 98 (66.7)
 Current smokers [No. (%)] 79 (52.8) 94 (63.9) 0.02 (X2 = 7.98)
 Alcohol drinkers [No. (%)] 100 (66.6) 90 (61.2) 0.46 (X2 = 1.55)
No. of UTI episodes (prior 12 months)
 Mean (SD) — 5.29 (6.0)
 Median — 6
 Range — 3–8
Table 1.  Baseline characteristics and descriptive statistics of participants (No. = 297). Keys: 
-rUTIs = Negative for recurrent urinary tract infections; + rUTIs = Positive for recurrent urinary tract 
infections; BMI = body mass index; CCI = Charlson Comorbidity Index. *P value according to chi-square test 
or analysis of variance (ANOVA), as indicated.
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Table 4 reports psychometric scores assessing urinary symptoms according to rUTIs status. Women with 
rUTIs showed higher mean IPSS scores (p = 0.003) and more frequently reported pathological storage symptoms 
than controls (p = 0.01). Conversely, no difference was observed between groups for voiding symptoms. Similarly, 
the IPSS-QoL domain score was higher in patients with rUTIs (p < 0.001).
Table 5 details the logistic regression models testing the associations between clinical predictors and patho-
logic psychometric scores. Model A, considering all participants, showed that age, total IPSS score and rUTIs 
were each associated with pathologic FSFI scores (all p ≤ 0.01). Conversely, CCI ≥ 1 and BMI were not. Similar 
findings were found for SDS scores. At logistic MVA, age, total IPSS score and rUTIs achieved independent 
predictor status for pathologic FSFI scores (all p ≤ 0.04) and for pathologic SDS scores (all p ≤ 0.02). Model B, 
focusing only on women with rUTIs, showed that age, total IPSS score, having ≥ 6 UTI episodes in the previous 
12 months and a history of constipation were univariably associated with pathologic FSFI scores (all p ≤ 0.01). 
Similar findings were found for SDS scores. At logistic MVA, age, total IPSS score, having ≥ 6 UTIs in the previous 
12 months, and a history of constipation achieved independent predictor status for both pathologic FSFI scores 
(all p ≤ 0.02) and pathologic SDS scores (all p ≤ 0.04).
Discussion
This study used validated psychometric tools to compare FSD prevalence and predictors in women with rUTIs 
to a group of same-age women not reporting UTI. Of clinical importance, nearly 8 out of 10 women with rUTIs 
reported scores suggestive for FSD. Likewise, women with rUTIs more frequently reported FSD compared to 
controls, with a significant impairment on the FSFI-pain, lubrication and arousal domains. Age, severity of LUTS, 
a history of ≥ 6 episodes of UTI over the previous 12 months and a history of constipation were independent 
predictors of FSD among rUTIs patients.
Our interest was fuelled by increasing evidence regarding the relationship between LUTS and FSD8,11. Several 
studies have suggested that women with OAB have high rates of sexual impairment11,12, and lower mean scores 
−rUTIs (No. = 150) +rUTIs (No. = 147) p-value (F)*
FSFI total score < 0.001 (69.23)
 Mean (SD) 63.7 (9.7) 17.6 (9.0)
 Range 7.0–92.0 1.2–35.4
Categorized FSFI total scores [No. (%)] < 0.001 (X2 = 31.1)
 Normal 118 (78.6) 31 (21.1)
 Pathological 32 (21.4) 116 (78.9)
FSFI domains, Mean (SD)
 Desire 4.0 (1.2) 3.7 (1.3) 0.21 (5.44)
 Arousal 4.1 (1.9) 2.7 (1.8) 0.001 (10.7)
 Lubrication 4.3 (2.1) 2.6 (1.8) < 0.001 (16.9)
 Orgasm 4.3 (2.1) 2.8 (2.3) < 0.01 (7.04)
 Satisfaction 4.4 (2.2) 3.4 (1.9) 0.02 (5.41)
 Pain 3.9 (2.2) 2.6 (1.7) 0.001 (10.76)
Pathological FSFI domains [No. (%)] 
 Desire 47 (31.2) 52 (35.6) 0.08 (X2 = 3.28)
 Arousal 39 (25.9) 75 (51.1) 0.02 (X2 = 5.79)
 Lubrication 32 (21.4) 77 (52.2) 0.008 (X2 = 7.10)
 Orgasm 27 (17.9) 69 (46.7) 0.01 (X2 = 6.66)
 Satisfaction 43 (28.6) 74 (50.1) 0.04 (X2 = 4.37)
 Pain 48 (32.1) 88 (60.0) 0.007 (X2 = 7.39)
SDS. < 0.001 (31.8)
 Mean (SD) 8.9 (6.9) 23.1 (12.6)
 Range 0–25 0–47
Categorized SDS Scores [No. (%)] < 0.001 (X2 = 29.5)
 Normal 118 (78.6) 33 (22.2)
 Pathological 32 (21.4) 114 (77.8)
Concomitant SDS/FSFI scores [No. (%)]
 nSDS/nFSFI 91 (60.7) 11 (7.8) < 0.001 (X2 = 36.4)
 pSDS/pFSFI 6 (3.6) 95 (64.4) < 0.001 (X2 = 31.6)
Table 2.  Psychometric scores assessing sexual function and sexual distress in the whole cohort (No. = 297). 
Keys: -rUTIs = Negative for recurrent urinary tract infections; + rUTIs = Positive for recurrent urinary tract 
infections; FSFI = Female Sexual Function Index; SDS = Sexual Distress Scale; nSDS/FSFI = normal SDS/FSFI; 
pSDS/FSFI = pathological SDS/FSFI; *P value according to chi-square test or analysis of variance (ANOVA), as 
indicated.
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for all domains of the FSFI, compared to healthy individuals13. Similarly, urgency and urinary incontinence (UI) 
have been frequently associated with FSD14,15.
The current results confirm previous findings showing a connection between LUTS and FSD. In fact, the 
higher the IPSS score in patients with rUTIs, the greater the progressive impairment of both FSFI and SDS scores. 
Previous studies assessing the relationship between LUTS and FSD found that 60% of patients with sexual arousal 
disorders and 61% with sexual pain disorders also complained of rUTIs8,13. Although the potential detrimental 
impact of rUTIs on QoL has been previously suggested6,7, the actual impact on women’s sexual functioning had 
never been comprehensively analysed. Therefore, the current findings are clinically relevant, because i) rUTIs are 
quite frequent in daily clinical practice; ii) they provide novel evidence for an association between rUTIs and FSD 
in sexually active, healthy women; iii) rUTIS were not only post-coital, as in previously published series16.
Taken together, the results of this real-life case-control study show that FSD prevalence among women with 
rUTIs was actually greater than that reported among women with classical LUTS8,11,13. Further corroborating this 
finding, sexual dysfunction was found in 47% of women with OAB and LUTS/UI8,13 while some degree of sexual 
impairment was reported by 19% to 50% of women with UI or pelvic floor disorders11,17. Focusing on the FSFI 
sub-domains, we found that women with rUTIs reported pathological scores of all domains, with the exception 
of sexual desire. These findings are in agreement with the complexity of sexual dysfunction previously observed 
among individuals suffering from LUTS/UI8, pure OAB13 or UI18 as a primary compliant.
Importantly, the FSFI-pain score was not only lower in patients with rUTIs compared to healthy women, but 
was pathological. To this regard, Salonia et al. recently showed that three out of five sexually active women of 
reproductive age whose primary complaint was rUTIs also suffered from secondary provoked vestibulodynia10.
We found that FSFI and SDS impairments were associated with age at presentation. These results corrobo-
rate previous findings showing that younger women tend to have greater sexual distress associated with urinary 
problems13,19, while women experiencing the menopause transition frequently experience a significant reduc-
tion of oestrogens at the genital level, which may be associated with or enhanced by the rUTIs themselves20. 
Importantly, to avoid confounding the effects of rUTI with effects experienced by post-menopausal women, in 
whom specific syndromes such as vulvovaginal atrophy become chronic and progressive21,22, we did not include 
post-menopausal women in the current study.
Recurrent cystitis is sometimes implicated with inflammation of the genitalia, vaginal lubrication disturbance 
and higher incidence of pain disorders. Moreover, vaginal dryness and low lubrication caused by urine in the 
vagina affects the normally acidic pH and may play a role in patients’ complaints. One could speculate that rUTIs 
may eventually trigger pelvic floor overactivity, thus predisposing the area to both microabrasion of the vestibular 
mucosa and microtrauma of the urethral area contributing to pain and discomfort during sexual intercourse. 
Moreover, rUTIs may lead to inflammation of the bladder mucosa with hyperactivation of the mast cells in the 
bladder wall and subsequent proliferation of pain nerve fibres in the bladder and urethral wall, leading to hyper-
algesia and allodynia during intercourse16.
FSFI p-value (F) SDS p-value (F) IPSS p-value (F)
Age 0.03 (3.5) 0.04 (3.2) 0.04 (3.2)
 18–25 24.1 (12.4) 11.2 (15.4) 8 (9.9)
 26–35 21.4 (9.6) 21.4 (11.3) 10.4 (5.2)
 36–50 16.5 (8.3) 24.1 (12.2) 13.2 (6.6)
BMI 0.87 (0.13) 0.14 (1.97) 0.27 (1.3)
 18.5–24.9 17.6 (9.0) 23.4 (12.5) 12.3 (6.5)
 25–29.9 18.4 (11.1) 15.6 (13.0) 13.1 (7.5)
 ≥ 30 15.3 (3.1) 30.3 (9.2) 18.6 (12.0)
CCI 0.61 (0.26) 0.49 (0.47) 0.72 (0.13)
 0 17.7 (8.8) 19.8 (17.3) 11.61 (4.1)
 ≥ 1 15.9 (11.0) 23.3 (12.2) 12.66 (7.0)
Bowel History < 0.001 (21.2) < 0.001 (24.2) < 0.001 (13.4)
 Normal 25.5 (8.7) 11.3 (10.6) 7.67 (6.2)
 Constipation 15.6 (7.9) 25.9 (11.4) 13.8 (6.4)
No. of UTI episodes (prior 12 months) 0.012 (6.7) 0.002 (10.3) 0.04 (3.51)
 ≥ 6 15.7 (9.1) 25.5 (13.5) 13.1 (6.6)
 ≤ 5 21.8 (9.5) 15.1 (12.1) 8.9 (6.3)
Categorized IPSS score 0.002 (5.44) < 0.001 (6.78)
 None 27.5 (2.2) 4.3 (4.5)
 Mild 21.8 (8.8) 19.43 (12.)
 Moderate 15.4 (7.5) 23.1 (11.9)
 Severe 14.8 (8.6) 31.6 (9.6)
Table 3.  Psychometric scores and clinical characteristics only in the groups of patients with rUTIs 
(No. = 147; [Mean (SD)]. Keys: rUTIs = recurrent urinary tract infections; IPSS = International Prostatic 
Symptoms Score; BMI = body mass index. CCI = Charlson Comorbidity Index. *P value according to ANOVA 
test of variance.
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Several data showed that cigarette smoking is one of the greatest risk factors for the development of blad-
der cancer23; likewise, the impact of smoking on promoting inflammation per se has been extensively reported. 
However, the impact of cigarette smoking on inducing bladder inflammation has been scantly analysed. Only one 
preclinical study illustrated the potential link between cigarette smoking and bladder inflammation mediated by 
the platelet-activating factor (PAF) accumulation and subsequent recruitment of inflammatory cells (i.e. mast 
cells) in the bladder wall24. Of clinical relevance, we found that women with rUTIs were more frequently current 
smokers that those without rUTIs. Thereof, it is possible to speculate that an increase in bladder inflammation 
mediated by cigarette smoking could act as an additional contributing factor for the development of rUTIs.
Of note, patients with rUTIs were less likely to be in a stable sexual relationship than controls in our cohort. 
This result is consistent with previous findings in premenopausal women where having multiple partners was 
reported as a strong behavioural risk factor for rUTIs1. Indeed, in a case-control study of women aged 18–30 
years, Scholes et al.25 showed that those with rUTIs had more frequent sexual intercourse and reported higher 
numbers of sexual partners than those without rUTIs. Overall, these risk factors were found to increase vaginal 
and urethral colonization with E. Coli1.
Even of clinical relevance, we found that women with rUTIs and a history of constipation had a 6-fold and 
5-fold higher risk of having pathologic FSFI and SDS scores, respectively. The significant association between 
constipation history and FSD is corroborated by the close relationship between constipation itself and the inci-
dence of rUTIs26. Some studies have suggested that the foecal flora acts as an optimal reservoir for the microbial 
strain that may subsequently recolonize the introitus and then the bladder, causing rUTIs26,27.
A potential strength of the study is that patients were enrolled at an outpatient clinic they had visited with 
a primary complaint of UTIs, therefore representing a typical real-life scenario. Additionally, this study high-
lights the importance of caregivers being more aware of the impact of rUTIs on women’s sexuality. Unfortunately, 
despite the scientific community frequently reporting the association between FSD and LUTS in women, this 
issue is still largely unknown or misunderstood by urologists and gynaecologists28. Thus, we are only begin-
ning to understand the causal/epiphenomenal relationship between rUTIs and distressful FSD. Therefore, a dia-
logue about sexual function in women with urinary infections should become an integral component of clinical 
management.
Our study is not devoid of limitations. The results were derived from a relatively small, homogenous cohort 
of women and deserve external validation with an independent, larger and more diverse sample. Our analyses 
lacked precise data on the frequency of penetrative vaginal or anal intercourse. Moreover, we also lacked com-
prehensive information regarding the specific real-time culture and thus were unable to exclude the possibility 
−rUTIs (No. = 150) +rUTIs (No. = 147) p value (F)*
Total IPSS score 0.003 (9.43)
 Mean (SD) 6.3 (5.1) 10.4 (6.5)
 Range 0–23 0–30
Categorized IPSS scores [No. (%)] 0.04 (X2 = 8.01)
 None 21 (14.3) 5 (3.3)
 Mild 75 (50.0) 56 (37.8)
 Moderate 48 (32.1) 65 (44.4)
 Severe 6 (3.6) 21 (14.4)
IPSS – Storage Scores < 0.001 (14.1)
 Mean (SD) 3.8 (2.7) 6.6 (3.7)
 Range 0–20 0–20
Categorized Storage symptoms [No. (%)] 0.01 (X2 = 9.14)
 None 27 (19.3) 20 (13.3)
 Mild 52 (34.6) 34 (23.3)
 Moderate to severe 71 (47.1) 93 (63.3)
IPSS – Voiding symptoms 0.12 (2.47)
 Mean (SD) 2.5 (3.1) 3.8 (3.9)
 Range 0–12 0–18
Categorized Voiding Scores [No. (%)] 0.01 (X2 = 9.20)
 None 59 (39.3) 20 (13.3)
 Mild 64 (42.9) 87 (58.9)
 Moderate to severe 27 (17.9) 40 (27.8)
IPSS – QoL score < 0.001 (60.1)
 Mean (SD) 0.9 (1.1) 3.4 (1.6)
 Range 0–3 0–6
Table 4.  Psychometric scores assessing urinary symptoms in the whole cohort (No. = 297).  
Keys: -rUTIs = Negative for recurrent urinary tract infections; + rUTIs = Positive for recurrent urinary tract 
infections; IPSS = International Prostatic Symptoms Score; QoL = Quality of life. *P value according to chi-
square test or analysis of variance (ANOVA), as indicated.
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of other vaginal pathogens not found in the urine samples. Further, we lacked data regarding the local hormonal 
milieu, which is clearly important for women’s urogynecologic and sexual health. Finally, being a real-life study 
we lack a baseline FSFI assessment before patients developed rUTIs.
In conclusion, this case-control study reports novel findings regarding the high prevalence of distressful sexual 
dysfunction among women suffering from rUTIs: nearly 80% of sexually-active women affected by rUTIs had psy-
chometric scores suggestive of sexual dysfunction. Overall, distressful sexual dysfunction emerged as a complex entity 
involving more than one aspect of sexual functioning, with the most significant impairments concerning sexual pain, 
lubrication and arousal. Of clinical importance, we found a positive association between FSD and patient age, severity 
of LUTS and a history of bowel constipation. Age, LUTS severity, having more than 6 episodes of UTIs throughout 
the previous 12 months, and a history of constipation were independent predictors of FSD. Overall, the current results 
indicate a clinical need for comprehensive investigations into the sexual health of women with UTIs, keeping in mind 
the extraordinary epidemiological impact that these uncomplicated infections can have on a woman’s quality of life.
Methods
From January 2014 to January 2016, demographic and clinical variables from 147 consecutively treated, white–
European, heterosexual, sexually-active women seeking medical help for symptomatic rUTIs at the same urologic 
outpatient clinic were considered for this exploratory, prospective analysis. An additional 3 patients were enrolled 
in the study but ultimately excluded due to incomplete data collection.
Patients were assessed with a thorough medical and sexual history. Health-significant comorbidities were 
scored with the Charlson Comorbidity Index (CCI)29, using the International Classification of Diseases, 9th revi-
sion. For our analysis, CCI was categorised as 0 or ≥ 1. All individuals were sexually active, with at least four 
occasions of sexual intercourse per month. The body mass index (BMI) of each patient was classified using the 
cut offs proposed by the National Institutes of Health (NIH): normal weight (18.5–24.9), overweight (25.0–29.9), 
and class ≥ 1 obesity (≥ 30.0).
Patients were excluded if younger than 18 or older than 50, if they had used combined hormonal contracep-
tion during the previous 6 months; if they were postmenopausal (either natural or surgical/iatrogenic), pregnant, 
breastfeeding or trying to conceive, if they had symptoms of upper UTI, a history of urinary tract anomalies/
vesicoureteral reflux, interstitial cystitis, diabetes, urinary tract stones, urinary incontinence, neurologic condi-
tions, clinical depression or depressive symptoms. A pelvic ultrasound assessment was performed in every patient 
during the baseline workup to rule out potentially relevant post-void residual. None of the patients in the study 
group had an indwelling catheter or used self-catheterization for any bladder dysfunction.
Urine cultures obtained through clean-catch samples (void after cleaning) were analysed. The microbiologic 
definition of UTI was 105 or more colony-forming units per milliliter from midstream. Recurrent UTI is defined 
as more than two symptomatic episodes of uncomplicated UTI within 6 months, or more than three within 
12 months, as documented by culture3,4. Symptomatic UTIs were defined through a detailed medical history.
Patients were defined as being in a stable relationship if they had the same sexual partner for 12 or more con-
secutive months. Prevalence of lower urinary tract symptoms (LUTS) was analysed in all subjects.
A total of 150 healthy age-matched sexually active women assessed in a routine gynaecological evaluation and 
no complaints of rUTIs (-rUTIs) over the last 3 years at least, were used as a cross-sectional control group.
All participants underwent a standard pelvic exam and no indications of abnormality were observed in any of 
the women in either group.
To provide a frame of reference for interpreting urinary dysfunction, all participants completed the 
International Prostatic Score Symptoms (IPSS)30.
Pathologic FSFI Pathologic SDS Pathologic FSFI Pathologic SDS
UVA MVA UVA MVA UVA MVA UVA MVA
Model A Model B
Age 1.3; < 0.001 [1.06–1.2]
1.10; 0.03 
[1.05–1.15]
1.16; < 0.002 
[1.08–1.24]
1.08; 0.025 
[1.01–1.17]
1.3; < 0.001 
[1.06–1.2]
1.22; 0.009 
[1.05–1.4]
1.16; < 0.002 
[1.08–1.24]
1.15; 0.021 
[1.02–1.3]
BMI 1.05; 0.40 [0.93–1.2]
1.06; 0.44 
[0.96–1.24]
1.01; 0.76 
[0.9–1.14]
1.01; 0.89 
[0.86–1.18]
1.05; 0.40 
[0.93–1.2]
1.05; 0.65 
[0.84–1.30]
1.01; 0.76 
[0.9–1.14]
0.96; 0.66 
[0.79–1.15]
CCI ≥ 1 0.58; 0.36 [0.18–1.8]
1.72; 0.53 
[0.32–9.36]
0.47; 0.53 
[0.9–1.14]
0.48; 0.38 
[0.09–2.42]
0.58; 0.36 
[0.18–1.8]
1.15; 0.91 
[0.08–8.81]
0.47; 0.53 
[0.9–1.14]
0.18; 1.21 
[0.02–1.55]
Tot IPSS 1.2; < 0.01 [1.08–1.3]
1.10; 0.04 
[1.02–1.2]
1.26; < 0.001 
[1.14–1.3]
1.2; 0.002 
[1.06–1.30]
1.2; < 0.01 
[1.08–1.3]
1.21; 0.02 
[1.02–1.4]
1.26; < 0.001 
[1.14–1.3]
1.2; 0.015 
[1.04–1.41]
+ rUTIs 13.7; < 0.001 [4.86–8.5]
7.69; < 0.001 
[2.49–7.78]
12.83; < 0.001 
[4.58–13.9]
5.68; 0.003 
[1.77–18.16] — — — —
— — — —
No. of UTI episodes (over the 
prior 12 months) ≥ 6 vs.< 6
6.2; 0.003 
[1.9–20.3]
9.3; 0.02 
[1.32–6.2]
7.31; < 0.001 
[2.38–22.3]
6.8; 0.022 
[1.31–5.30]
Constipation history  
Yes vs. No
12.3; < 0.001 
[3.8–20.2]
6.32; 0.03 
[1.22–6.6]
16.1; < 0.001 
[4.8–18.3]
4.9; 0.04 
[1.08–9.8]
Table 5.  Logistic regression models predicting pathologic psychometric scores (OR; p value [95%CI]) 
in the whole cohort (Model A; No. = 297) and only in women with rUTIs (Model B; No. = 147). Keys: 
UVA = Univariable analyses; MVA = Multivariable analyses; CCI = Charlson Comorbidity Index; BMI = body 
mass index; + rUTIs = Positive for recurrent urinary tract infections.
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To assess sexual dysfunction and sexual distress profiles, patients also completed The Female Sexual Function 
Index (FSFI)31 and the Female Sexual Distress Scale (SDS)32. The FSFI was categorized according to the cut-off 
value of 26.55 proposed by Wiegel et al., whereas SDS was dichotomized according to the median value33.
Data collection was carried out following the principles outlined in the Declaration of Helsinki; after approval 
of the IRCCS San Raffaele Hospital’s Ethical Committee, all patients signed an informed consent agreeing to 
supply their own anonymous data for this and future studies.
Data are presented as means (SD; ranges). The statistical significance of differences in means and proportions was 
tested with the one-way analysis of variance (ANOVA) and Pearson chi-square test, respectively. A 95% confidence 
interval was estimated for the association of categorical parameters. Exploratory analyses were initially applied to all 
variables; variables were retained for analysis when deemed clinically significant to the results. We performed two 
logistic regression models. Model A assessed potential predictors of FSD in the whole population. Logistic regression 
univariable analysis (UVA) and multivariable analysis (MVA) tested the associations between clinical predictors (e.g. 
age, BMI, CCI, IPSS, rUTIs) and pathologic psychometric scores (FSFI and SDS). Conversely, model B tested the asso-
ciation between predictors (age, BMI, CCI, IPSS, number of UTI episodes in the last 12 months according to median 
value, constipation history) and the presence of pathologic psychometric scores in women with rUTIs. Statistical anal-
yses were performed using SPSS statistical software, version 20 (IBM Corp, Armonk, NY). All tests were 2-sided with 
a significance level of 0.05.
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